"Disappointing revenue predictions": Danish pharmaceutical company Novo Nordisk reduces profit projections
In a recent announcement, Danish drugmaker Novo Nordisk has revealed that it is facing significant market challenges for its blockbuster GLP-1 drugs Ozempic (diabetes) and Wegovy (weight loss) in the US. The company has lowered its full-year earnings forecasts, but specific reasons for the adjustments have not been disclosed.
The challenges include increased competition, particularly from Eli Lilly’s competing GLP-1 obesity drug Zepbound, slower-than-expected market expansion for obesity treatments, and the continued availability and use of compounded (copycat) versions of semaglutide despite FDA regulatory crackdowns. This illegal mass compounding has persisted even after the expiry of the FDA’s grace period in May 2025, continuing to undercut Wegovy sales.
As a result, Novo Nordisk has revised its 2025 sales growth forecast from 13-21% to 8-14% and trimmed operating profit growth estimates from 16-24% to 10-16%. The company reported an 18% increase in first-half sales but experienced a slowdown in profit growth compared to the previous year.
To tackle these challenges, Novo Nordisk has appointed Maziar Mike Doustdar, the current head of international operations, as its new president and CEO. The company sees him as best positioned to lead Novo Nordisk through this difficult period with a fresh global perspective and renewed strategic focus. The chairman noted the urgency to respond quickly and ambitiously to recent market developments.
Investors have viewed the leadership change positively, hoping Doustdar will reinvigorate the company’s strategy amid "continued incretin pressure" in the US market. The specific actions the new CEO plans to take to address the market challenges have not been disclosed.
The dominance of Ozempic and Wegovy in the US pharmaceutical market is being challenged by rivals, and the company’s upcoming earnings releases will be closely watched for signs of stabilization or further erosion in core revenue streams.
If you have any questions or suggestions, feel free to email us at news@our website. We also invite you to join a conversation in the comments section below. You can log in and leave a comment using the link provided.
[1] [Article 1] [2] [Article 2] [3] [Article 3] [4] [Article 4] [5] [Article 5]
Please note that comments must adhere to our terms of use.
This article does not mention any other products besides Ozempic and Wegovy. Other related articles in our publication include "What income do you need to buy a home in Denmark in 2025?", "Food, sport and love: How does the average Dane really live?", "What foreigners find surprisingly cheap in Denmark and annoyingly expensive", and "Denmark's Great Belt Bridge to open toll gates after 15 minutes in event of outage".
- The art of managing Novo Nordisk's challenges in the US market, particularly the increasing competition and the continued use of compounded semaglutide drugs, will be crucial for the new CEO, Maziar Mike Doustdar, in sustaining the company's financial growth.
- In light of the financial industry's keen interest in Novo Nordisk's performance, the business community and investors will closely monitor the news related to the company's earnings releases, seeking signs of stabilization or further loss in the revenue streams of its blockbuster GLP-1 drugs Ozempic and Wegovy.
